Head-to-head evidence
Beclomethasone (QVAR) vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Beclomethasone (QVAR)
Marketed by Teva Pharmaceutical Industries
NCT00109668 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with over 400 patients, which gives it solid design fundamentals. However, no results have been posted, and the record does not state what the primary outcome measure actually was, so the strength of the eventual evidence cannot yet be confirmed.
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00158834 · Phase 3 · completed
The study randomized 200 children and used double blinding with an active fluticasone comparator. Its primary endpoint was the clinical measure of asthma symptom-free days, but no results are posted, so whether that endpoint was met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone (QVAR)'s landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape